Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Relative Bioavailability of Emraclidine in Healthy Adults
NCT05933187Phase 1Completed
- Sponsor
- Cerevel Therapeutics
- Start
- Jul 2023
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of emraclidine in schizophrenia (4 arms), sponsored by Cerevel Therapeutics. Primary endpoints: Maximum Observed Plasma Concentration at 96 hours, Time to Maximum Plasma Concentration at 96 hours and 2 more. Started Jul 2023; status: completed.
02
Drugs
emraclidine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT05933187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05933187.